Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 2, 2010, Pages 511-522

  Morichetti, D ^a   Mazzucchelli, R ^a   Santinelli, A ^a   Stramazzotti, D ^a   Lopez Beltran, A ^b   Scarpelli, M ^a   Bono, A V ^a   Cheng, L ^c   Montironi, Rodolfo ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

High grade prostatic intraepithelial neoplasia; NE differentiation; Prostate cancer; Somatostatin receptors

Indexed keywords

SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ADULT; AGED; ARTICLE; CELL MEMBRANE; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENDOTHELIUM CELL; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SECRETORY CELL; SMOOTH MUSCLE;

EID: 77955408428     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300213     Document Type: Article

References (30)

1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179:77-9.
2. Epelbaum J, Dournaud P, Fodor M, Viollet C. The neurobiology of somatostatin. Crit Rev Neurobiol 1994; 8:25-44.
3. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20:157-198.
4. Kumar U. Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis. Neuroscience 2005; 134:525-38.
5. Casini Raggi C, Calabro A, Renzi D, et al. Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa. Clin Cancer Res 2002; 8:419-27.
6. Portela-Gomes MG, Stridsberg M, Grimelius L, Oberg K, Janson ET. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol 2000; 8:126-32.
7. Balster AD, O'Dorisio MS, Summers MA, Turman MA. Segmental expression of somatostatin receptor subtypes sst(1) and sst(2) in tubules and glomeruli of human kidney. Am J Physiol Renal Physiol 2001; 280:457-65.
8. Hansson J, Bjartell A, Gadaleanu V, Dizeyi N, Abrahamsson PA. Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate 2002; 53:50-9.
9. Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 1995; 80:2806-14.
10. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest 2005; 28:36-42.
11. Klisovic DD, O'Dorisio MS, Katz SE, Sall JW, Balster D, O'Dorisio TM, Craig E, Lubow M. Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study. Invest Ophthalmol Vis Sci 2001; 42:2193-201.
12. Verset G, Verslype C, Reynaert H, et al. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer 2007; 97:582-8.
13. Montironi R, Cheng L, Mazzucchelli R, et al. Immunohistochemical detection and localization of somatostatin receptor subtypes in prostate tissue from patients with bladder outlet obstruction. Cell Oncol 2008; 30:473-82.
14. Morichetti D, Mazzucchelli R, Stramazzotti D, Santinelli A, Lopez-Beltran A, Scarpelli M, Bono AV, Cheng L, Montironi R. Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer. BJU Int 2009 (in press).
15. Barbisan F, Mazzucchelli R, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montorsi F, Montironi R. Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies. Eur Urol 2009; 56:105-12.
16. Mazzucchelli R, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R. Immunohistochemical expression of Prostate Stem Cell Antigen (PSCA) in cystoprostatectomies with incidental prostate cancer. Int J Immunopathol Pharmacol 2009; 22:755-762.
17. Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Scarpelli M, Lopez Beltran A HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol 2006; 37:1137-44.
18. Santinelli A, Mazzucchelli R, Barbisan F, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R. alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer. Am J Clin Pathol 2007; 128:657-66.
19. Dizeyi N, Konrad L, Bjartell A, Wu H, Gadaleanu V, Hansson J, Helboe L, Abrahamsson PA. Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 2002; 7:91-8.
20. Egevad L. Recent trends in Gleason grading of prostate cancer. II. Prognosis, reproducibility and reporting. Anal Quant Cytol Histol 2008; 30:254-60.
21. Helboe L, Møller M, Nørregaard L, Schiødt M, Stidsen CE. Development of selective antibodies against the human somatostatin receptor subtypes sst1-sst5. Brain Res Mol Brain Res 1997; 49:82-8.
22. Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab 2000; 85:2564-71.
23. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994; 54:3455-9.
24. Volante M, Brizzi MP, Faggiano A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of a scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007; 20:1172-82.
25. Hornick CA, Anthony CT, Hughey S, Gebhardt BM, Espenan GD, Woltering EA. Progressive nuclear translocation of somatostatin analogs. J Nucl Med 2000; 41:1256-63.
26. Gernone A, Pagliarulo V, Trabucco S. Prognostic role of somatostatin receptor subtypes in human prostate cancer. J Clin Oncol 2009; 27(S):16120.
27. Curtis SB, Hewitt J, Yakubovitz S, Anzarut A, Hsiang YN, Buchan AM. Somatostatin receptor subtype expression and function in human vascular tissue. Am J Physiol Heart Circ Physiol 2000; 278:1815-22.
28. Badway AC, West FM, Tente SM, Blake AD. Somatostatin regulates intracellular signaling in human carotid endothelial cells. Biochem Biophys Res Commun 2004; 319:1222-7.
29. Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med 1997; 70:471-9.
30. Cariaga-Martinez AE, Lorenzati MA, Riera MA, et al. Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and Phosphotyrosine Phosphatase SHP-1 (PTPN6) according to tumor progression. Adv Urol 2009 (Epub).